Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter

Inclusion Criteria: * All patients 18 years of age or older, with hepatocellular carcinoma are eligible. * Patients must have a life expectancy of at least 12 weeks. * Patients must have a ECOG performance status of 0-2. * Patients must sign an informed consent. * Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of \> 1,500 or cells/mm3 and platelet count \>100,000/mm3 and absence of a regular red blood cell transfusion requirement. * Patients should have adequate hepatic function with a total bilirubin \< 2 mg/dl and SGOT or SGPT \< two times the upper limit of normal, and adequate renal function as defined by a serum creatinine \< 1.5 x upper limit of normal. * There must be one measurable lesion according to the RECIST criteria that should not have had prior radiation treatment. Exclusion Criteria: * Patients with symptomatic brain metastases that had not been adequately and definitively treated with radiation and/or surgical resection are excluded from this study. * Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception. * Patients may receive no other concurrent chemotherapy or radiation therapy during this trial. * Patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections are not eligible for this trial. * Life expectancy of less than 12 weeks. * Serious, uncontrolled concurrent infection(s) * Any prior treatment with, Gemcitabine or Oxaliplatin . * Completion of previous chemotherapy regimen less than 4 weeks, prior to start of this study or persistence of prior treatment related toxicity. * Treatment for other carcinomas within the last five years, except for cured non-melanoma of the skin and treated in-situ cervical cancer. * Participation in any investigational study within 4 weeks preceding the start of the study treatment. * Clinically significant heart disease defined as NYHA class 3 or 4 heart disease. * Chronic debilitating diseases that the investigator feels might compromise the study Participation. * Evidence of inadequately treated CNS metastases. * Major surgery within 4 weeks of the s1art of the study treatment without complete recovery. * Known or existing uncontrolled coagulopathy. * Any of the following laboratory parameters v) Abnormal hematological values with ANC less than 1500/mm3, thrombocytopenia less than 99,000. vi) Impaired renal function with a serum creatinine of greater than 1.5 ULN vii) Serum bilirubin greater than 1.5xULN viii) Albumin less than 2.5mg/dl. * Unwillingness to give informed consent. * Unwillingness to participate or inability to comply with the protocol for the duration of the study.